| Autor: |
Lucchetta, RC, Riveros, BS, Pontarolo, R, Radominski, RB, Otuki, MF, Fernandez-Llimos, F, Correr, CJ |
| Rok vydání: |
2017 |
| Předmět: |
|
| Popis: |
© 2017 CLINICS. The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients. A systematic review of primary studies was conducted, followed by a direct meta-analysis (random effect) and mixed treatment comparison. Medline and other databases were searched. Heterogeneity was explored through I2 associated with a p-value. Of 739 identified publications, 25 were included in the meta-analysis. The global evaluation of Cochrane resulted in 19 studies with a high level of bias and six with unclear risk. Due to the lack of information in primary studies, direct meta-analyses were conducted only for amfepramone and mazindol. Compared to placebo, amfepramone resulted in higher weight loss in the short-term ( |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
